Startups
Edit
Viralgen Vector Core
https://viralgenvc.com/Last activity: 09.03.2023
Active - Reference to Viralgen
Viralgen Vector Core becomes the convergence point from experienced specialized organizations in biotechnology and life science fields, united with the aim of creating a CDMO in the sector of gene therapy and innovative medicines. Developing and manufacturing in order to contribute to the progress in health and welfare of people. Viralgen Vector Core is a partnership uniquely positioned in the CDMO industry to bring forward a robust suspension platform for AAV production in a facility custom-designed to bring therapies to market as quickly as possible. Leveraging the technology platforms of Askbio, Viralgen is able to support every aspect of your AAV program from start to finish, including large-scale manufacturing, fill-finish, and quality control in a GMP-certified environment in San Sebastian, Spain
Overview
Location
Spain, Autonomous Community of the Basque Country, San Sebastián
Employees
201-500
Founded date
2017
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 9, 2023 | Viralgen erhält cGMP-Zertifizierung für die Herstellung von rAAV-Produkten in kommerzieller Qualität in neuer Anlage in San Sebastian, Spanien | /EIN News/ -- -- Die Zertifizierung erweitert die Kapazitäten von Viralgen um das Dreifache und positioniert das Unternehmen als weltweit führende CDMO -- -- Die neue Anlage betreibt Einweg-Bioreaktoren mit einem Volumen von 50 bis 2.000 Li... |
| Jan 9, 2023 | Viralgen reçoit la certification cBPF pour fabriquer un AAVr de qualité commerciale sur un nouveau site à Saint-Sébastien, en Espagne | /EIN News/ -- -- La certification multiplie par trois la capacité de Viralgen et positionne l'entreprise en tant que CDMO de premier plan au niveau mondial -- -- Le nouveau site exploite des bioréacteurs à usage unique de 50 à 2 000 litres ... |
| Jan 17, 2022 | GMP production of CG01 made available for preclinical studies planned to enable First in Human study | STOCKHOLM — CombiGene AB (‘CombiGene’) and Spark Therapeutics (‘Spark‘), a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic ... |
| Jul 1, 2021 | A viral vector player is expanding its footprint in Basque Country amid heightened demand | As the demand for viral vectors grows unabated amid the Covid-19 pandemic, a CDMO is dropping a serious investment to build out a new Basque Country facility. The new facility is in the same technology park as Viral... |
| Jul 1, 2021 | Horizon takes the leap into manufacturing, buying out an Irish plant with around 40 employees in tow | Horizon Therapeutics, the biotech known for scooping up orphan drugs, has made its first foray into manufacturing with the purchase of a facility in Waterford, Ireland. EirGen Pharma has sold its site to Horizon for $6... |
| Jul 1, 2021 | Catalent bags a German stem cell developer to build its next-gen therapeutics wing | Another day, another acquisition for CDMO giant Catalent. The New Jersey firm has now bought out German’s RheinCell Therapeutics, a specialist in human induced pluripotent stem cells, to build out its next-gen therapi... |
| Jun 19, 2020 | El CDTI concede 2,9M en subvenciones a siete proyectos empresariales de I+D frente al COVID-19 | 19/06/2020 Nota de prensa EL CDTI CONCEDE €2,9 MILLONES EN SUBVENCIONES A SIETE PROYECTOS EMPRESARIALES DE I+D FRENTE AL COVID-19. Estas ayudas forman parte de la convocatoria extraordinaria lanzada para apoyar proyectos destinados a inc... |
| Mar 21, 2019 | ColumbusVP financia íntegramente la construcción de la nueva planta de producción de Viralgen con entre 15 y €20 millones | 21/03/2019 COLUMBUS VENTURE PARTNERS FINANCIA ÍNTEGRAMENTE LA CONSTRUCCIÓN DE LA NUEVA PLANTA DE PRODUCCIÓN DE VIRALGEN CON ENTRE 15 Y €20 MILLONES. La entidad de capital riesgo (venture capital) Columbus Venture Partners, ha cerrado la s... |
Reviews 0
FAQ about Viralgen Vector Core
When was Viralgen Vector Core founded?
Viralgen Vector Core was founded in 2017.
What has the press written about Viralgen Vector Core?
Parsers VC has collected 9 articles mentioning Viralgen Vector Core, among them “Viralgen erhält cGMP-Zertifizierung für die Herstellung von rAAV-Produkten in kommerzieller Qualität in neuer Anlage in San Sebastian, Spanien” (Jan 9, 2023) and “Viralgen reçoit la certification cBPF pour fabriquer un AAVr de qualité commerciale sur un nouveau site à Saint-Sébastien, en Espagne” (Jan 9, 2023).
Is Viralgen Vector Core still active?
Yes, Viralgen Vector Core is active; its latest activity on Parsers VC dates from Mar 9, 2023.